FDA accepts Tzield sBLA for stage 2 type 1 diabetes in children as young as 1 year
The FDA has accepted for priority review a supplemental biologics license application (sBLA) for teplizumab-mzwv (Tzield; Sanofi) that seeks to expand the current age indication from 8 years and older…